Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in solid tumors with PALB2 mutations
NCT05169437Phase 2Terminated
- Sponsor
- Tempus AI
- Start
- Mar 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in breast cancer, colon cancer, lung cancer and 6 more, sponsored by Tempus AI. Primary endpoint: Overall Response Rate at 4 years. Started Mar 2022; status: terminated.
02
Drugs
niraparib
03
Conditions
breast cancercolon cancerlung cancerurologic cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05169437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169437.